0      0

AONN+ Annual 2020

FRI14 - Product Theater 4 | Treatment of Patients in Newly Diagnosed Multiple Myeloma: Patient Adherence and Dose Modifications in Response to Adverse Events (non-CE) Presentation by Bristol-Myers Squibb

Nov 6, 2020 4:00pm ‐ Nov 6, 2020 5:00pm


This program will share information about a treatment option for newly diagnosed multiple myeloma including the impact of multiple myeloma on patients, dose modifications for consideration due to adverse events, and approaches to keep patients on therapy.

  • Multiple myeloma disease impact
  • Information about a treatment option for patients with NDMM
  • Disease impact of multiple myeloma
  • Dose modifications due to adverse events
  • Patient education and resources


You must be logged in and own this session in order to post comments.